Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years

Inclusion Criteria:

• Participants must have a documented erosive lesion with an Los Angeles (LA) Grade ofA to D prior to starting Proton Pump Inhibitor treatment:

• Capable of giving signed informed consent/assent

• Willingness and ability of the participant or parent/legal guardian to complete theeDiary

• Willing and able to comply with all scheduled visits, treatment plan, laboratorytests, lifestyle considerations, and other study procedures, including the use ofthe eDiary.

• Male and female participants aged 1 to 17 years.

• Minimum body weight 7 kilogram and weight at least at the 5th percentile per theCenter for Disease Control standard age and weight chart, for the participant's age.

• To be considered a female of non childbearing potential, the participant must meetat least 1 of the following criteria :

• Premenarchal: The investigator (or other appropriate staff) must discuss theparticipant's premenarchal status with the participant and parent/legal guardian atoffice visits and during telephone contacts, as participants who achieve menarcheduring the study would no longer be considered "female participants of nonchildbearing potential" and must comply with the protocol requirements applicable towomen of childbearing potential.

Exclusion Criteria:

• Previous administration of an investigational drug or vaccine within 30 days (or asdetermined by the local requirement) or 5 half-lives preceding the first dose ofstudy intervention used in this study (whichever is longer).

• Children that may be at high risk from procedural sedation should be carefullyevaluated. Participants with a history of complications during prior proceduralsedation

• History or presence of upper gastrointestinal anatomic or motor disorders

• Family history of malignant hyperthermia

• Known hypersensitivity to any Proton Pump Inhibitor, including pantoprazole or toany substituted benzimidazole or to any of the excipients.

• Any disorder requiring chronic (daily) use of warfarin, heparin, otheranticoagulants, methotrexate, atazanavir or nelfinavir, clopidogrel, or potentinhibitors or inducers of CYP2C19 (eg, phenytoin, sulfamethoxazole, valproic acid,carbamazepine, and griseofulvin).

• Serum creatine kinase levels >3 x upper limit of normal.

• Known history of human immunodeficiency virus or clinical manifestations of acquiredimmune deficiency syndrome.

• Active malignancy of any type, or history of a malignancy. Participants with ahistory of malignancies that have been surgically removed or eradicated byirradiation or chemotherapy and who have no evidence of recurrence for at least 5years before Screening are acceptable.

• Diagnosed as having or has received treatment for esophageal, gastric, pyloricchannel, or duodenal ulceration within 30 days before the Screening visit.

• Alanine aminotransferase or blood urea nitrogen >2.0 upper limit of normal orestimated creatinine >1.5 X upper limit of normal for age or any other laboratoryabnormality considered by the Investigator to be clinically significant within 14days before the Baseline Visit (Day 1).

• Other acute or chronic medical or psychiatric condition including recent (within thepast year) or active suicidal ideation or behavior or laboratory abnormality thatmay increase the risk associated with study participation or study interventionadministration or may interfere with the interpretation of study results and, in thejudgment of the investigator, would make the participant inappropriate for entryinto this study.

• Has, in the Investigator's opinion, a serious chronic condition (eg, diabetes,epilepsy), which is either not stable or not well controlled and may interfere withthe conduct of the study.

• Has any condition possibly affecting drug absorption (eg, gastrectomy).

Prior or Concomitant Therapy:

• Frequent, repeated use of oral or parenteral glucocorticoids (eg, prednisone,prednisolone, dexamethasone). Steroid inhalers and topical steroids may be used.

• Pregnant female participants; breastfeeding female participants.

• Is unwilling or unable to comply with the Lifestyle Considerations section